# Robert P. Giugliano

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-p-giugliano/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,483 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 106 |
| i10-index | 405 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5045665978 |
| ORCID iD | https://orcid.org/0000-0003-4110-7675 |
| Works | 840 |

## Researcher papers

- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [Edoxaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/edoxaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials](https://scholariq.org/papers/comparison-of-the-efficacy-and-safety-of-new-oral-anticoagulants-with-warfarin/)
- [Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes](https://scholariq.org/papers/ezetimibe-added-to-statin-therapy-after-acute-coronary-syndromes/)
- [TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation](https://scholariq.org/papers/timi-risk-score-for-st-elevation-myocardial-infarction-a-convenient-bedside/)
- [Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial](https://scholariq.org/papers/cardiovascular-safety-and-efficacy-of-the-pcsk9-inhibitor-evolocumab-in-patients/)
- [Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study](https://scholariq.org/papers/efficacy-safety-and-tolerability-of-a-monoclonal-antibody-to-proprotein-2/)
- [Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF](https://scholariq.org/papers/nonvitamin-k-anticoagulant-agents-in-patients-with-advanced-chronic-kidney/)
- [Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48](https://scholariq.org/papers/performance-of-the-abc-scores-for-assessing-the-risk-of-stroke-or-systemic/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.